



# Maternal height and risk of gestational diabetes: a systematic review and meta-analysis

Ahmed Arafa<sup>1,2</sup> · Jia-Yi Dong<sup>1</sup>

Received: 27 March 2019 / Accepted: 13 May 2019 / Published online: 20 May 2019  
© Springer-Verlag Italia S.r.l., part of Springer Nature 2019

## Abstract

**Aims** Identifying women at high risk of developing gestational diabetes mellitus (GDM) is a public health interest. This study aims to investigate the association between maternal height and risk of GDM through meta-analysis.

**Methods** We retrieved the studies that assessed maternal height in relation to GDM. Pooled risk estimates of the included articles and their 95% confidence intervals (95% CIs) were calculated using a fixed- or random-effects model. Subgroup analyses were conducted according to study design and study location. Quality of studies was determined using the Newcastle–Ottawa Scale. Publication bias was detected using the Egger’s and Begg’s tests.

**Results** A total of 10 studies including 7 cohort and 3 cross-sectional studies with a total of 126,094 women were included for meta-analysis. Combined, each 5-cm increase in height was associated with about 20% reduction in risk of GDM [pooled odds ratio = 0.80, (95% CI 0.76, 0.85)]. The analysis revealed high heterogeneity between studies which dissolved after subgroup analysis by study design. This significant association did not differ between Asian and non-Asian populations. Egger’s and Begg’s tests showed little evidence of publication bias.

**Conclusions** The present meta-analysis supports the conception that short stature is associated with GDM. Further studies of high quality are needed to confirm the findings.

**Keywords** Height · Stature · Gestational diabetes · Meta-analysis

## Introduction

The prevalence of gestational diabetes mellitus (GDM) has been increasing over time [1]. GDM carries a high risk of adverse pregnancy outcomes and long-term consequences for both mothers and their offspring [2]. For instance, mothers with a history of GDM were more likely to develop type 2 diabetes [3, 4] and cardiovascular disease [5], and their children were also at an increased risk of insulin resistance and obesity [6, 7]. Therefore, identifying women at risk of

GDM with the aim of applying monitoring approaches and prevention strategies is considered a public health interest.

Advanced age at pregnancy, obesity, and family history of diabetes are well-known risk factors of GDM [8]. Emerging evidence has suggested a link between height and risk of GDM. Anastasiou et al. reported that short stature was inversely correlated with glucose tolerance among pregnant women [9]. Subsequent studies showed a higher risk of GDM among women with short stature, though the magnitude of the association differed between studies [10–19].

Previous studies examining height and GDM had several limitations, including limited sample size and lack of control for important risk factors. Furthermore, individual studies used different cutoffs to define short and tall participants. For example, in the study by Rudra et al., subjects  $\leq 160$  cm were defined as having short stature [13], while Li et al. [18] assigned subjects  $\geq 158$  cm to the tall stature category. Herein, we aimed to study whether women’s height is associated with GDM by conducting a meta-analysis of available evidence.

---

Managed by Antonio Secchi.

✉ Jia-Yi Dong  
dongjy@mail3.sysu.edu.cn

<sup>1</sup> Public Health, Department of Social Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan

<sup>2</sup> Department of Public Health, Faculty of Medicine, Beni-Suef University, Beni Suef, Egypt

## Methods

### Searching strategy

The present meta-analysis was reported according to the checklist of MOOSE [20] and the checklist of PRISMA [21]. Two investigators independently searched MEDLINE (PubMed), Web of Science, and Cochrane Library for potential studies published in English before January 31, 2019, using the following search terms: (height OR stature) AND (gestational diabetes mellitus OR diabetes mellitus in pregnancy OR pregnancy diabetes mellitus). No time restrictions were imposed. We searched for additional studies by a manual review of the reference lists of retrieved articles. Only published full-text articles were searched, and no effort was made to identify unpublished studies.

### Eligibility criteria

We first scanned the titles and abstracts identified by the electronic search before conducting a full-text search in case of uncertainty about relevance. Studies were included for meta-analysis if they met the following criteria: The study was conducted in humans, and risk estimates in the form of odds ratios (ORs) or relative risks (RRs) with their 95% confidence intervals (CIs) between maternal height and GDM were provided.

### Study selection

The authors conducted the literature search independently by reviewing the full manuscript of all articles detected by the primary search. Then, the extracted articles were subjected to the above-mentioned eligibility criteria to reach a list of studies to be included in this meta-analysis. Relevant information was extracted from the selected studies: last name of the first author, publication year, country, sample size, study design, cutoffs of height, assessment methods of GDM, adjusted risk estimate with corresponding 95% CIs, and quality of study as determined using the Newcastle–Ottawa Scale. When a given study presented different models that adjusted for several potential confounders, we included the model that adjusted for the largest number of confounders. Two investigators individually extracted the data and assessed the study quality, with differences resolved by discussion.

### Statistical analysis

ORs and their CIs were used as measures of the association. RR was considered as OR directly. We converted the

ORs of GDM for each 5-cm increment in height if they were reported for each 1-cm increment.  $I^2$  was calculated to test statistical heterogeneity across studies [22], and a fixed-effects model or in the presence of heterogeneity a random-effects model was used to compute the pooled ORs [23]. Subgroup analyses were conducted according to study design (cross-sectional, retrospective cohort, and prospective cohort studies) and study location (Asia, Europe or the United States). We conducted a sensitivity analysis to identify the influence of a single study on the pooled ORs by removing studies one by one and combining the remainders in separate analyses. Publication bias was assessed using Begg's test [24] and Egger's test [25]. All analyses were conducted using STATA 12.

## Results

The primary literature search retrieved 1273 studies, and most of them were excluded because they were duplication reports ( $n = 631$ ), reviews ( $n = 10$ ), or not relevant ( $n = 590$ ). Among 42 studies for full-text review, 32 studies were excluded because they did not report the risk estimates and corresponding CIs for the association. Finally, 10 studies were included for this meta-analysis (Fig. 1).

Characteristics of the studies are shown in Table 1. Of them, 5 were prospective cohort studies, 2 were retrospective cohort studies, and 3 were cross-sectional studies. They were published between 1998 and 2018, with a total population of 126,094 women. Among them, 4 studies were conducted in Asia, 3 in Europe, 2 in the USA, and 1 in Brazil. The cutoffs used to differentiate between shortest and tallest




Fig. 1 Flowchart of the study selection process

**Table 1** Characteristics of the included studies

References	Country	Sample	Design	Diabetes Diagnosis	Shortest versus tallest category of height	Covariates	Quality
Jang et al. [10]	Korea	9005	CS	OGTT	≤ 157 versus ≥ 163	1, 2	Poor
Branchtein et al. [11]	Brazil	5564	PC	OGTT	≤ 151 versus ≥ 160	1, 2, 3, 4, 5, 6, 7	Good
Yang et al. [12]	China	9741	CS	OGTT	NA	1, 2, 4, 5, 6, 7	Fair
Rudra et al. [13]	USA	1644	PC	OGTT	≤ 160 versus > 170	1, 2, 3, 4	Good
Ogonowski et al. [14]	Poland	2841	RC	OGTT	NA	1, 2, 6, 7	Fair
Brite et al. [15]	USA	135,861	RC	Medical record	< 157.5 versus > 167.7	1, 2, 3, 4	Good
Syngelaki et al. [16]	UK	75,161	CS	OGTT	NA	1, 2, 3, 6, 7	Fair
Mendoza et al. [19]	Europe	971	PC	OGTT	≤ 169 versus > 169	1, 2, 3, 4, 5, 6, 7	Good
Li et al. [18]	China	19,962	PC	OGTT	< 158 versus ≥ 158	1, 3, 4, 5, 6	Good
Li et al. [17]	China	6941	PC	OGTT	≤ 158 versus > 164	1, 2, 4, 5	Good

Covariates: 1: age, 2: weight, 3: race/ethnicity, 4: education, 5: parity, 6: family history of diabetes, 7: previous gestational diabetes  
 CS cross-sectional, NA not available, OGTT oral glucose tolerance test, PC prospective cohort, RC retrospective cohort


categories varied among the studies. All included studies but one used the oral glucose tolerance test to diagnose GDM. Most adjusted covariates included age, weight, race/ethnicity, education level, parity, family history of diabetes, and previous history of GDM.

Eight studies provided ORs of GDM for each 1-cm or 5-cm increment in height, and all of them reported a significant inverse association between height and GDM. All combined, each 5-cm increment in height was associated with about 20% reduction in risk of GDM (pooled OR = 0.80, 95% CI 0.76, 0.85) (Fig. 2). There was a high degree of

heterogeneity among studies ( $I^2 = 72.7%$ ,  $p$  value for heterogeneity = 0.001). Stratified analysis by study design obtained ORs (95% CI) of 0.74 (0.71, 0.78), 0.80 (0.78, 0.82), and 0.89 (0.83, 0.95) for the cross-sectional, retrospective cohort, and prospective cohort studies, respectively. We observed no evidence of heterogeneity within each study design (all  $I^2 < 10%$ , all  $p$  value for heterogeneity > 0.35).

We further conducted a stratified analysis by study area. The results were following: pooled ORs were 0.82 (95% CI 0.72, 0.94) in Asia ( $n = 3$ ) and 0.75 (95% CI 0.72, 0.79) in Europe or the USA ( $n = 4$ ), respectively. There was a

**Fig. 2** Meta-analysis of the studies examining the association between heights and risk of gestational diabetes [odds ratio (OR) for each 5-cm increment in height]



significant heterogeneity among studies conducted in Asia ( $I^2 = 69.2\%$ ,  $p$  value for heterogeneity = 0.04) but not in studies conducted in Europe or the USA ( $I^2 = 0$ ,  $p$  value for heterogeneity = 0.45). Although the association appeared to be weaker in Asian studies, the difference did not reach statistical significance ( $p$  value for interaction = 0.31). Also, results of sensitivity analysis indicated that no single study had a substantial impact on the overall risk, with pooled ORs ranging from 0.78 (95% CI 0.74, 0.82) to 0.82 (95% CI 0.77, 0.87). Egger's and Begg's tests showed little evidence of publication bias (both  $p$  values for publication bias > 0.65).

In addition, we conducted a meta-analysis by combining ORs for the highest versus the lowest category of height. As shown in Fig. 3, women in the tallest category, compared with those in the shortest category had a lower risk of GDM (pooled OR = 0.53, 95% CI 0.38, 0.73), with strong evidence of heterogeneity observed ( $I^2 = 88.6\%$ ,  $p$  value for heterogeneity < 0.001). Heterogeneity disappeared among studies with a prospective cohort design ( $I^2 = 20\%$ ,  $p$  value for heterogeneity = 0.29).

## Discussion


In this meta-analysis, we found that each 5-cm increment in height was associated with about 20% reduction in risk of GDM. The results were stable as shown by the stratified and sensitivity analyses and were independent of the study design and study area.

We observed a high degree of heterogeneity between studies, which was not unexpected given the different study design of individual studies, the wide variations in the racial and socio-demographic characteristics of the subjects included. By a stratified analysis, we were able to identify study design as a possible contributor to the heterogeneity observed. In addition, a relatively weaker association among prospective cohort studies indicated that the results from cross-sectional and retrospective cohort studies might have been affected by the limitations of such study design, including the lack of control for important confounders, as shown in Table 1, and possibly the selection and misclassification biases.

In the subgroup analysis by study area, the association between height and GDM remained significant and did not significantly differ between Asian and non-Asian populations, suggesting that the height–GDM association may be independent of ethnicities. In agreement with our finding, Brite et al. detected an inverse association between height and GDM among white, black, Hispanic, and Asian USA women. However, in their study, the magnitude of the association varied significantly across ethnicities, with a significantly stronger association observed in Asian populations than that in other populations [15].

Short stature has been shown to be associated with increased risk of many non-communicable diseases. For example, previous meta-analyses showed that the shortest women had a 14% higher likelihood of type 2 diabetes compared to the tallest women [26] and that increased height led to a reduction in the risk of coronary heart

**Fig. 3** Meta-analysis of the studies examining the association between height and risk of gestational diabetes [odds ratio (OR) for highest versus lowest category of height]



diseases [27]. In addition, a recent meta-analysis of 20 prospective studies reported that each 5-cm increment in height was associated with a 7% and 12% reduction in the risk of stroke among men and women, respectively [28].

Although the mechanisms underlying the association between short stature and risk of GDM are uncertain, the theory of shared risk factors can partially explain the findings. Nutritional, socioeconomic, and genetic factors have significant impacts on women's height and may affect their susceptibility to GDM as well [11]. It has been reported that inadequate childhood nutrition increases the risk of both short stature and diabetes during adulthood [29] and that the insufficient release of growth hormones, attributed to childhood malnutrition, is associated with short stature and impaired glucose tolerance in adulthood [30]. The role of socioeconomic status is supported by earlier studies which have shown that low socioeconomic position during childhood was a risk factor for short stature and diabetes [31, 32]. In contrast, Li et al. [17] conducted subgroup analysis by educational level and detected an inverse association between height and GDM across all subgroups suggesting a relationship between short stature and GDM regardless of the educational level.

Previous cross-sectional studies showed that adult short stature was associated with obesity [33, 34], which is also an established risk factor of GDM. On the other hand, there is little evidence from prospective studies examining whether adult height is independently associated with weight gain or risk of obesity. Such evidence, if any, could support the notion that short stature increases the risk of GDM mediated by weight gain and obesity. Besides, short stature and impaired glucose tolerance may share some genetic risk factors. For example, one study showed that participants who carried the risk alleles in the gene for the insulin-like growth factor I associated with a shorter height and increased risk of type 2 diabetes [35].

It should be noted that this meta-analysis had some limitations. Firstly, each study had its unique definition for short stature which may have resulted in a high degree of heterogeneity. We, therefore, conducted the main analysis by combining the risk estimates for every 5-cm increment in height, which to some extent reduced the heterogeneity. Secondly, several studies used self-reported height, which most likely causes measurement error. Thirdly, several studies did not adjust their results for potential confounders such as educational level, family history of diabetes, and previous history of GDM. Thus, residual confounding remained an alternative explanation for the observed association. Fourthly, in addition to the limited number of studies included, half of them were of cross-sectional or retrospective cohort design which may be more prone to biases than prospective studies. Finally, publication bias is always a threat to the validity of meta-analysis although

we observed little evidence of such bias by the formal tests.

In conclusion, the results of the present meta-analysis support the conception that short stature is associated with GDM. Further studies of high quality are needed to confirm the findings of this study.

**Author contributions** AA collected the data, analyzed the data, and wrote the manuscript. JYD designed the study, collected the data, analyzed the data, conducted the technique review, and reviewed and edited the manuscript. JYD is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Funding** This work was partly supported by Japan Society for the Promotion of Science KAKENHI Grant Numbers A18H063910 and T19K214700. Role of the Funder: The funder had no role in the conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript findings.

## Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

**Statement of human and animal rights** This article does not contain any studies with human or animal subjects performed by the any of the authors.

**Informed consent** For this type of study informed consent is not required.

## References

1. Kampmann U, Madsen LR, Skajaa GO, Iversen DS, Moeller N, Ovesen P (2015) Gestational diabetes: a clinical update. *World J Diabetes* 6(8):1065–1072. <https://doi.org/10.4239/wjcd.v6.i8.1065>
2. Buchanan TA, Xiang AH, Page KA (2012) Gestational diabetes mellitus: risks and management during and after pregnancy. *Nat Rev Endocrinol* 8(11):639–649. <https://doi.org/10.1038/nrendo.2012.96>
3. Bellamy L, Casas JP, Hingorani AD, Williams D (2009) Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. *Lancet (London, England)* 373(9677):1773–1779. [https://doi.org/10.1016/s0140-6736\(09\)60731-5](https://doi.org/10.1016/s0140-6736(09)60731-5)
4. Li J, Song C, Li C, Liu P, Sun Z, Yang X (2018) Increased risk of cardiovascular disease in women with prior gestational diabetes: A systematic review and meta-analysis. *Diabetes Res Clin Pract* 140:324–338. <https://doi.org/10.1016/j.diabres.2018.03.054>
5. McKenzie-Sampson S, Paradis G, Healy-Profitos J, St-Pierre F, Auger N (2018) Gestational diabetes and risk of cardiovascular disease up to 25 years after pregnancy: a retrospective cohort study. *Acta Diabetol* 55(4):315–322. <https://doi.org/10.1007/s00592-017-1099-2>
6. Boerschmann H, Pfluger M, Henneberger L, Ziegler AG, Hummel S (2010) Prevalence and predictors of overweight and insulin resistance in offspring of mothers with gestational diabetes

- mellitus. *Diabetes Care* 33(8):1845–1849. <https://doi.org/10.2337/dc10-0139>
7. Maftel O, Whitrow MJ, Davies MJ, Giles LC, Owens JA, Moore VM (2015) Maternal body size prior to pregnancy, gestational diabetes and weight gain: associations with insulin resistance in children at 9–10 years. *Diabetic Med* 32(2):174–180. <https://doi.org/10.1111/dme.12637>
  8. Ali AD, Mehrass AA, Al-Adhroey AH, Al-Shammakh AA, Amran AA (2016) Prevalence and risk factors of gestational diabetes mellitus in Yemen. *Int J women's Health* 8:35–41. <https://doi.org/10.2147/ijwh.s97502>
  9. Anastasiou E, Alevizaki M, Grigorakis SJ, Philippou G, Kyprianou M, Souvatzoglou A (1998) Decreased stature in gestational diabetes mellitus. *Diabetologia* 41(9):997–1001. <https://doi.org/10.1007/s001250051022>
  10. Jang HC, Min HK, Lee HK, Cho NH, Metzger BE (1998) Short stature in Korean women: a contribution to the multifactorial predisposition to gestational diabetes mellitus. *Diabetologia* 41(7):778–783. <https://doi.org/10.1007/s001250050987>
  11. Branchtein L, Schmidt MI, Matos MC, Yamashita T, Pousada JM, Duncan BB (2000) Short stature and gestational diabetes in Brazil. Brazilian Gestational Diabetes Study Group. *Diabetologia* 43(7):848–851
  12. Yang X, Hsu-Hage B, Zhang H et al (2002) Gestational diabetes mellitus in women of single gravidity in Tianjin City, China. *Diabetes Care* 25(5):847–851
  13. Rudra CB, Sorensen TK, Leisenring WM, Dashow E, Williams MA (2007) Weight characteristics and height in relation to risk of gestational diabetes mellitus. *Am J Epidemiol* 165(3):302–308. <https://doi.org/10.1093/aje/kwk007>
  14. Ogonowski J, Miazgowski T (2010) Are short women at risk for gestational diabetes mellitus? *Eur J Endocrinol* 162(3):491–497. <https://doi.org/10.1530/eje-09-0992>
  15. Brite J, Shiroma EJ, Bowers K, Yeung E, Laughon SK, Grewal JG, Zhang C (2014) Height and the risk of gestational diabetes: variations by race/ethnicity. *Diabetic Med* 31(3):332–340. <https://doi.org/10.1111/dme.12355>
  16. Syngelaki A, Pastides A, Kotecha R, Wright A, Akolekar R, Nicolaides KH (2015) First-trimester screening for gestational diabetes mellitus based on maternal characteristics and history. *Fetal Diagn Therapy* 38(1):14–21. <https://doi.org/10.1159/000369970>
  17. Li H, Song L, Shen L et al (2018) Height and risk of gestational diabetes mellitus: results from the healthy baby cohort study. *J Diabetes Res* 2018:4679245. <https://doi.org/10.1155/2018/4679245>
  18. Li J, Wang P, Zhang C et al (2018) Short body height and pre-pregnancy overweight for increased risk of gestational diabetes mellitus: a population-based cohort study. *Front Endocrinol* 9:349. <https://doi.org/10.3389/fendo.2018.00349>
  19. Mendoza LC, Harreiter J, Simmons D et al (2018) Risk factors for hyperglycemia in pregnancy in the DALI study differ by period of pregnancy and OGTT time point. *Eur J Endocrinol* 179(1):39–49. <https://doi.org/10.1530/eje-18-0003>
  20. Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. *JAMA* 283(15):2008–2012
  21. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ (Clinical research ed)* 339:b2535. <https://doi.org/10.1136/bmj.b2535>
  22. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. *BMJ (Clinical research ed)* 327(7414):557–560. <https://doi.org/10.1136/bmj.327.7414.557>
  23. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. *Control Clin Trials* 7(3):177–188
  24. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. *Biometrics* 50(4):1088–1101
  25. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. *BMJ (Clinical research ed)* 315(7109):629–634
  26. Janghorbani M, Momeni F, Dehghani M (2012) Hip circumference, height and risk of type 2 diabetes: systematic review and meta-analysis. *Obes Rev* 13(12):1172–1181. <https://doi.org/10.1111/j.1467-789X.2012.01030.x>
  27. Nuesch E, Dale C, Palmer TM et al (2016) Adult height, coronary heart disease and stroke: a multi-locus Mendelian randomization meta-analysis. *Int J Epidemiol* 45(6):1927–1937. <https://doi.org/10.1093/ije/dyv074>
  28. Zhou W, Li Y, Liu X et al (2019) Sex-specific relationship between adult height and the risk of stroke: a dose–response meta-analysis of prospective studies. *J Clin Hypertens (Greenwich, Conn)* 21(2):262–270. <https://doi.org/10.1111/jch.13458>
  29. Yeung EH, Hu FB, Solomon CG et al (2010) Life-course weight characteristics and the risk of gestational diabetes. *Diabetologia* 53(4):668–678. <https://doi.org/10.1007/s00125-009-1634-y>
  30. Wang Z, Rowley K, Wang Z, Piers L, O'Dea K (2007) Anthropometric indices and their relationship with diabetes, hypertension and dyslipidemia in Australian Aboriginal people and Torres Strait Islanders. *Eur J Cardiovasc Prev Rehabil* 14(2):172–178. <https://doi.org/10.1097/01.hjr.0000220580.34763.fb>
  31. Barros AJ, Victora CG, Horta BL, Goncalves HD, Lima RC, Lynch J (2006) Effects of socioeconomic change from birth to early adulthood on height and overweight. *Int J Epidemiol* 35(5):1233–1238. <https://doi.org/10.1093/ije/dyl160>
  32. Tsenkova V, Pudrovskaya T, Karlamangla A (2014) Childhood socioeconomic disadvantage and prediabetes and diabetes in later life: a study of biopsychosocial pathways. *Psychosom Med* 76(8):622–628. <https://doi.org/10.1097/psy.000000000000106>
  33. Asao K, Kao WH, Baptiste-Roberts K, Bandeen-Roche K, Erlinger TP, Brancati FL (2006) Short stature and the risk of adiposity, insulin resistance, and type 2 diabetes in middle age: the Third National Health and Nutrition Examination Survey (NHANES III), 1988–1994. *Diabetes Care* 29(7):1632–1637. <https://doi.org/10.2337/dc05-1997>
  34. Bosy-Westphal A, Plachta-Danielczik S, Dorhofer RP, Muller MJ (2009) Short stature and obesity: positive association in adults but inverse association in children and adolescents. *Br J Nutr* 102(3):453–461. <https://doi.org/10.1017/S0007114508190304>
  35. Vaessen N, Heutink P, Janssen JA et al (2001) A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. *Diabetes* 50(3):637–642

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.